AVROBIO Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

AVROBIO General Information

Description

Developer of lentiviral-based gene therapies designed to halt or reverse Lysosomal disorders with a single dose. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen and for the treatment of Pompe disease.

Contact Information

Website
www.avrobio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Technology Square
  • 6th Floor
  • Cambridge, MA 02139
  • United States
Primary Industry
Biotechnology
Acquirer
Tectonic Therapeutic
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 100 Technology Square
  • 6th Floor
  • Cambridge, MA 02139
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AVROBIO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 20-Jun-2024 Completed Generating Revenue
9. Merger/Acquisition 08-Feb-2023 Cancelled Generating Revenue
8. Secondary Transaction - Open Market Completed Generating Revenue
7. Secondary Transaction - Open Market Completed Generating Revenue
6. Secondary Transaction - Open Market 28-Sep-2018 Completed Clinical Trials - Phase 2
5. IPO 21-Jun-2018 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 02-Feb-2018 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 30-Mar-2017 Completed Clinical Trials - Phase 2
2. Accelerator/Incubator 01-Jun-2016 $1.5M Completed Startup
1. Seed Round 18-Feb-2016 $1.5M $1.5M Completed Startup
To view AVROBIO’s complete valuation and funding history, request access »

AVROBIO Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
Seed 3,333,333 $0.000100 $0.02 $0.45 $0.45 1x $0.45 4.19%
To view AVROBIO’s complete cap table history, request access »

AVROBIO Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of lentiviral-based gene therapies designed to halt or reverse Lysosomal disorders with a single dose. The com
Biotechnology
Cambridge, MA
13 As of 2023

Lexington, MA
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AVROBIO Competitors (65)

One of AVROBIO’s 65 competitors is Voyager Therapeutics, a Corporation company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Corporation Lexington, MA
Orchard Therapeutics Formerly VC-backed London, United Kingdom
Alaunos Therapeutics Formerly VC-backed Houston, TX
TScan Therapeutics Formerly VC-backed Waltham, MA
Biosceptre Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 65 competitors. Get the full list »

AVROBIO Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AVROBIO Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
5Y Capital Venture Capital Minority
Aisling Capital Venture Capital Minority
Atlas Venture Venture Capital Minority
Brace Pharma Capital Corporate Venture Capital Minority
Citadel Enterprise Americas Hedge Fund Minority
You’re viewing 5 of 9 investors. Get the full list »

AVROBIO Acquisitions (1)

AVROBIO’s most recent deal was a Reverse Merger with Tectonic Therapeutic for . The deal was made on 30-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tectonic Therapeutic 30-Jan-2024 Reverse Merger Drug Discovery
To view AVROBIO’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

AVROBIO ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

27 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,480

Rank

Percentile

Pharmaceuticals

Industry

of 905

Rank

Percentile

Biotechnology

Subindustry

of 404

Rank

Percentile

To view AVROBIO’s complete esg history, request access »

AVROBIO FAQs

  • When was AVROBIO founded?

    AVROBIO was founded in 2015.

  • Where is AVROBIO headquartered?

    AVROBIO is headquartered in Cambridge, MA.

  • What is the size of AVROBIO?

    AVROBIO has 13 total employees.

  • What industry is AVROBIO in?

    AVROBIO’s primary industry is Biotechnology.

  • Is AVROBIO a private or public company?

    AVROBIO is a Private company.

  • What is AVROBIO’s current revenue?

    The current revenue for AVROBIO is .

  • How much funding has AVROBIO raised over time?

    AVROBIO has raised $187M.

  • Who are AVROBIO’s investors?

    5Y Capital, Aisling Capital, Atlas Venture, Brace Pharma Capital, and Citadel Enterprise Americas are 5 of 9 investors who have invested in AVROBIO.

  • Who are AVROBIO’s competitors?

    Voyager Therapeutics, Orchard Therapeutics, Alaunos Therapeutics, TScan Therapeutics, and Biosceptre are some of the 65 competitors of AVROBIO.

  • When was AVROBIO acquired?

    AVROBIO was acquired on 20-Jun-2024.

  • Who acquired AVROBIO?

    AVROBIO was acquired by Tectonic Therapeutic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »